Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01899105 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01899105 is a Phase 1 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 28 participants.
The verdict
NCT01899105, a Phase 1 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study is designed to investigate the effect of food on the relative bioavailability of 2 different strengths of fixed-dose combinations of lumacaftor and ivacaftor tablet formulations.
Interventions
- DRUG ivacaftor
- DRUG lumacaftor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2013-07 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01899105
The ClinicalTrials.gov registry entry for NCT01899105 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ivacaftor is the first listed.
NCT01899105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01899105 about?
NCT01899105 is a clinical study titled "A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor". This study is designed to investigate the effect of food on the relative bioavailability of 2 different strengths of fixed-dose combinations of lumacaftor and ivacaftor tablet formulations.
What is the current status of trial NCT01899105?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2013-07. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01899105?
The interventions under investigation include: ivacaftor (DRUG), lumacaftor (DRUG).
Who is sponsoring clinical trial NCT01899105?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.